Molecular mechanisms of tumour budding and its association with microenvironment in colorectal cancer
- PMID: 35445707
- DOI: 10.1042/CS20210886
Molecular mechanisms of tumour budding and its association with microenvironment in colorectal cancer
Abstract
Colorectal cancer (CRC) is the third most common cancer worldwide. Poor survival of CRC associated with the development of tumour metastasis led to the investigation of the potential biomarkers to predict outcomes in CRC patients. Tumour budding (TB) is a well-known independent prognostic marker for poor survival and disease metastasis. Therefore, it has been suggested that TB status is included in routine clinicopathological factors for risk assessment in CRC. In contrast with a vast majority of studies regarding the prognostic power of TB, there is no clear evidence pertaining to the underlying molecular mechanism driving this phenotype, or an understanding of TB relationship with the tumour microenvironment (TME). The aim of the present study is to present a comprehensive review of TB and tumour cell signalling pathways together with the cross-talk of immune cells that could drive TB formation in CRC.
Keywords: Colorectal cancer; Tumour budding; immune response; molecular mechanisms.
© 2022 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.
Similar articles
-
Tumour budding - an additional prognostic factor in colorectal cancer survival.Pol J Pathol. 2023;74(1):36-41. doi: 10.5114/pjp.2023.127040. Pol J Pathol. 2023. PMID: 37306351
-
Histopathological tumour microenvironment score independently predicts outcome in primary operable colorectal cancer.J Pathol Clin Res. 2024 May;10(3):e12374. doi: 10.1002/2056-4538.12374. J Pathol Clin Res. 2024. PMID: 38650367 Free PMC article.
-
The relationship between tumour budding, the tumour microenvironment and survival in patients with primary operable colorectal cancer.Br J Cancer. 2016 Jul 12;115(2):156-63. doi: 10.1038/bjc.2016.173. Epub 2016 Jun 14. Br J Cancer. 2016. PMID: 27299960 Free PMC article.
-
Tumour budding is a novel marker in breast cancer: the clinical application and future prospects.Ann Med. 2022 Dec;54(1):1303-1312. doi: 10.1080/07853890.2022.2070272. Ann Med. 2022. PMID: 35535687 Free PMC article. Review.
-
Intraepithelial tumour infiltrating lymphocytes are associated with absence of tumour budding and immature/myxoid desmoplastic reaction, and with better recurrence-free survival in stages I-III colorectal cancer.Histopathology. 2021 Jan;78(2):252-264. doi: 10.1111/his.14211. Epub 2020 Sep 14. Histopathology. 2021. PMID: 32654226 Free PMC article. Review.
Cited by
-
Cellular and Molecular Mechanisms of the Tumor Stroma in Colorectal Cancer: Insights into Disease Progression and Therapeutic Targets.Biomedicines. 2023 Aug 23;11(9):2361. doi: 10.3390/biomedicines11092361. Biomedicines. 2023. PMID: 37760801 Free PMC article. Review.
-
Tumor budding and the prognosis of patients with metastatic colorectal cancer: a meta-analysis.Int J Colorectal Dis. 2023 May 24;38(1):141. doi: 10.1007/s00384-023-04423-8. Int J Colorectal Dis. 2023. PMID: 37222838 Review.
-
Multi-omics analysis to uncover the molecular basis of tumor budding in head and neck squamous cell carcinoma.NPJ Precis Oncol. 2025 Mar 13;9(1):73. doi: 10.1038/s41698-025-00856-2. NPJ Precis Oncol. 2025. PMID: 40082664 Free PMC article.
-
A novel cuproptosis-related molecular pattern and its tumor microenvironment characterization in colorectal cancer.Front Immunol. 2022 Sep 30;13:940774. doi: 10.3389/fimmu.2022.940774. eCollection 2022. Front Immunol. 2022. PMID: 36248908 Free PMC article.